Современные возможности медикаментозной терапии артериальной гипертензии. Место кандесартана
Аннотация
Об авторах
О. Л. БарбарашРоссия
В. В. Кашталап
Россия
Список литературы
1. Wolf-Maier K, Cooper R.S, Banegas J.R et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003; 289: 2363–9.
2. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертензия: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Рос. кардиол. журн. 2006; 4: 45–50.
3. Чазова И.Е., Ратова Л.Г., Бойцов С.А. Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Системные гипертензии. 2010; 3: 5–27.
4. ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281–357.
5. Skov K, Eiskjur H, Hansen H.E et al. Treatment of young subjects at high familial risk of future hypertension with an angiotensin - receptor blocker. Hypertens 2007; 50: 89–95.
6. Koh K.K, Quon M.J, Lee Y et al. Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients. Eur Heart J 2007; 28: 1440–7.
7. Meredith P.A. Candesartan cilexetil – a review of effects on cardiovascular complications in hypertension and chronic heart failure. Curr Med Research Opin 2007; 23 (7): 1693–705.
8. Michel M.C, Foster C, Brunner H.R et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 2013; 65 (2): 809–48.
9. Van Vark L, Bertrand M, Akkerhuis M et al. Angiotensin - converting enzyme inhibitors reduce mortality in hypertension: a meta - analysis of randomized clinical trials of renin - angiotensin - aldosterone system inhibitors involving 158 988 patients. Eur Heart J 2012; 33: 2088–97.
10. Марцевич С.Ю. Ингибиторы ангиотензинпревращающего фермента и антагонисты рецепторов ангиотензина: есть ли основания говорить о равенстве двух классов препаратов с позиций доказательной медицины? Рацион. фармакотерапия в кардиологии. 2013; 9 (4): 427–32.
11. Гиляревский С.Р., Орлов В.А., Кузьмина И.М., Голшмид М.В. «Ингибиторы ангиотензинпревращающего фермента или сартаны у больных с высоким риском развития осложнений сердечно - сосудистых заболеваний» – неправильный вопрос или нежелательный ответ? Системные гипертензии. 2013; 1: 35–8.
12. Mancia G, Schumacher H, Redon J et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation 2011; 124: 1727–36.
13. Еремина Ю.Н., Леонова М.В., Галицкий А.А. Антагонисты рецепторов к ангиотензину II: обзор эффективности и безопасности. Cons. Med. 2013; 15 (1): 25–9.
14. Heran B.S, Wong M.M, Heran I.K, Wright J.M. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Datab Syst Rev 2008; 4: CD003822.
15. Cernes R, Mashavi M, Zimlichman R. Candesartan compared to other angiotensin receptor blockers. Vasc Health Risk Management 2011; 7: 749–59.
16. Барышникова Г.А., Чорбинская С.А., Степанова И.И., Чупрова Н.В. Роль олмесартана в клинической практике. Cons. Med. 2013; 15 (1): 18–22.
17. Detroja C, Chavhan S, Sawant K. Enhanced antihypertensive activity of candesartan cilexetil nanosuspension: formulation, characterization and pharmacodynamic study. Sci Pharm 2011; 79: 635–51.
18. Israili Z.H. Clinical pharmacokinetics of angiotensin II [AT1] receptor blockers in hypertension. J Hum Hypertens 2000; 14: 73–86.
19. Mc Clellan K.J, Goa K.L. Candesartan cilexetil: a review of its use in essential hypertension. Drugs 1998; 56: 847–69.
20. Hirokazu M, Taro E, Koji N et al. Solid - state characterization of candesartan cilexetil [TCV-116]: crystal structure and molecular mobility. Chem Pharm Bull 1999; 47: 182–6.
21. Kurtz T.W, Kajiya T. Differential pharmacology and benefit/risk of azilsartan compared to other sartans. Vasc Health Risk Management 2012; 8: 133–43.
22. Reif M, White W.B, Fagan T.C et al. Effects of candesartan cilexetil in patients with systemic hypertension [Candesartan Cilexetil Study Investigators]. Am J Cardiol 1998; 82: 961–5.
23. Thurmann P.A, Kenedi P, Schmidt A et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037–42.
24. Wong M, Staszewsky L, Latini R et al. Valsartan benefits left ventricular structure and function in heart failure: Val–HeFT echocardiographic study. J Am Coll Cardiol 2002; 40: 970–5.
25. Cuspidi C, Muiesan M.L, Valagussa L et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293–300.
26. Ларина Н.В., Самохвалова В.В. Ишемический инсульт: генетические и возрастные аспекты (обзор литературы). Пробл. старения и долголетия. 2012; 21 (1): 73–96.
27. Ducharme A, Swedberg K, Pfeffer M.A et al. Prevention of atrial fibrillation in patients with symtomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 151: 985–91.
28. Lithell Y, Hansson L, Skoog I et al. The Study on COgnition and Prognosis in the Elderly (SCOPE): principal results of randomized double - blind intervention trial. J Hypertens 2003; 21: 875–80.
29. Lithell Y, Hansson L, Skoog I et al. The Study on COgnition and Prognosis in the Elderly (SCOPE): outcomes in patients not receiving add - on therapy after randomization. J Hypertens 2004; 22: 1605–12.
30. Schrader J, Lucers S, Kulschewski A et al. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34: 1699–703.
31. Ariff B, Zambonini A, Vamadeva S et al. Candesartan - and atenolol - based treatments induce different patterns of caritod artery and left ventricular remodeling in hypertension. Stroke 2006; 37: 2381–8.
32. Schmieder R.E, Martin S, Lang G.E et al. Angiotensin blockade to reduce microvascular damage in diabetes mellitus. Deutsches Ärzteblatt International Dtsch Arztebl Int 2009; 106 (34–35): 556–62.
33. Gaede P, Lund-Andersen H, Parving H.H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580–91.
34. Grimm et al. New - onset diabetes and antihypertensive treatment. GMS Health Technol Assessment 2010; 6: 1–11.
35. Okpechi I.G, Rayner B.L. Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction. Integrated Blood Pressure Control 2010; 3: 45–55.
36. Yusuf S, Ostergren J.B, Gerstein H.C et al. Effects of candesartan on the development of new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005; 112: 48–53.
37. Chaturvedi N, Sjoelie A.K, Svensson A. The Diabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. J Renin Angiotensin Aldosterone Syst 2002; 3: 255–61.
38. Chaturvedi N, Porta M, Klein R et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo - controlled trials. Lancet 2008; 372: 1394–402.
39. Sjolie A.K, Klein R, Porta M et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo - controlled trial. Lancet 2008; 372: 1385–93.
40. Schmieder R.E, Schrader J, Zidek W et al. Low - grade albuminuria and cardiovascular risk: What is the evidence? Clin Res Cardiol 2007; 96: 247–57.
41. Mogensen C.E, Neldam S, Tikkanen I et al. Randomized controlled trial of dual blockade of renin - angiotensin system in patient with hypertension, microalbuminuria, and non - insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 2000; 321: 1440–4.
42. Schmieder R.E, Klingbeil A.U, Fleischmann E.H et al. Additional antiproteinuric effect of ultrahigh dose candesartan: a doubleblind, randomized, prospective study. J Am Soc Nephrol 2005; 16: 3038–45.
43. Burgess E.D, Muirhead N, De Cotret P.R. A double - blind randomized controlled trial of high dose candesartan cilexetil in proteinuric renal disease – results from SMART (Supra Maximal Atacand Renal Trial). ASN Online 2007.
44. Kunz R, Friedrich C, Wolbers M, Mann J.F. Meta - analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30–48.
45. Zheng Z, Shi H, Jia J et al. A systematic review and meta - analysis of candesartan and losartan in the management of essential hypertension. J Renin Angiotensin Aldosterone System 2011; p. 1–10.
46. Dykewicz M.S. Cough and angioedema from angiotensinconverting enzime inhibitors: new insights into mechanisms and management. Curr Opin Allergy Clin Immunol 2004; 4: 267–70.
Рецензия
Для цитирования:
Барбараш О.Л., Кашталап В.В. Современные возможности медикаментозной терапии артериальной гипертензии. Место кандесартана. Системные гипертензии. 2013;10(4):55-58.
For citation:
Barbarash O.L., Kashtalap V.V. Modern possibilities of hypertension drug therapy. Candesartan and its place in the therapy. Systemic Hypertension. 2013;10(4):55-58.
Послать статью по эл. почте 